Weekly FDA Roundup: April 4–10, 2026
FDA drops 7 GLP-1 warning letters in one coordinated sweep — the enforcement focus has broadened from compounders and telehealth to raw peptide vendors and eBay arbitrage sellers. Plus three device early alerts, a DSCSA fraud warning at a med spa, and a Wellcovorin NDA withdrawal.
27 items this week — 12 warning letters, 3 recalls, 3 safety alerts, 8 notices, 1 guidance.
The dominant story is a coordinated enforcement wave against online peptide vendors. Everything else was secondary noise.
The Story: FDA Drops 7 GLP-1 Warning Letters in One Day
On April 7, CDER issued simultaneous warning letters to seven companies selling unapproved injectable GLP-1/peptide drugs over the internet:
- Mile High Compounds LLC — Semaglutide, Tirzepatide, Retatrutide, bacteriostatic water
- Prime Sciences — Cagrilintide, Retatrutide, Semaglutide, Tirzepatide, Mazdutide
- Lovega LLC (Pink Pony Peptides) — Tirzepatide, Retatrutide
- Gram Peptides — Retatrutide, Tirzepatide
- PekCura Labs — GLP-1-S, GLP-2-T, GLP-3-R, Cagrilintide/Tirzepatide blend
- FormPour — "SMGT-GLT-1 Nano Microneedle Patch" (semaglutide) sold on eBay
- Guangzhou Huli Technology Co. (Fantasy Face) — "Googeer GLP-1 Weight Control Oral Solution" sold on eBay
The pattern across all seven is the same: products labeled "for research use only" but marketed with explicit disease and weight management claims — obesity treatment, blood sugar control, metabolic improvement. FDA cited FD&C Act Section 505(a) in each case. The "research only" disclaimer does not insulate sellers; FDA applies an intent test based on the surrounding marketing claims.
Two of the seven (FormPour and Fantasy Face) were selling through eBay storefronts — an indicator that FDA's enforcement sweep is moving beyond dedicated peptide e-commerce sites and into general marketplace platforms.
This follows the March 2026 wave of warning letters against telehealth companies for compounded GLP-1 marketing. The enforcement focus has now broadened from compounders and telehealth to raw peptide vendors and e-commerce arbitrage sellers. Companies in the peptide supply chain — including vendors who market "research" quantities of GLP-1 analogs — face elevated risk.
Device Safety: Three Early Alerts
Cook Medical — Centimeter Sizing Catheter (April 9) Cook Medical issued an early alert for several models of Centimeter Sizing Catheters due to marker bands that may crack or break. Fragmentation or separation inside the vascular system can cause vessel injury or life-threatening harm. Healthcare providers are instructed to stop use, quarantine inventory, and return affected devices. FDA is treating this as high-risk under 21 CFR 803/806.
Baxter Healthcare — Volara Single-Patient Use Circuits (April 9) FDA classified Baxter's correction of Volara Single-Patient Use Circuits as a Class I–level action. The Volara system can interfere with home care ventilators, causing oxygen desaturation or barotrauma. Baxter has issued an IFU addendum; users should monitor for respiratory distress. This continues a pattern — Baxter has had multiple Volara-related enforcement actions since 2022, with affected accessories distributed through December 2023 still working through the corrective action pipeline.
AVID Medical — Convenience Kit Early Alert (April 10) FDA issued an early alert for an AVID Medical convenience kit issue. Early alerts flag high-risk device issues before formal recall classification — the signal for providers is to pause use and check inventory against the affected lot range while the corrective action works through FDA's classification pipeline.
Drug Supply Chain: DSCSA Fraud at a Med Spa
FDA issued a warning letter to Pure Indulgence Aesthetics (April 9) for violations of the Drug Supply Chain Security Act. The firm dispensed substantially more units of Botox than it purchased from authorized trading partners — a discrepancy FDA uses as a proxy for sourcing from gray or counterfeit channels. Inspectors also found an unlabeled vial containing botulinum neurotoxin type A on the premises. This matters beyond one med spa: DSCSA enforcement against aesthetic injector practices is accelerating, and the unlabeled vial finding typically triggers parallel criminal referral review.
Recall Watch
Blaine Labs Wound Care Gels (April 8) Voluntary nationwide recall of three lots of Revitaderm and Tridergel Wound Care Gels (0.1% Benzalkonium Chloride) due to contamination with Lysinibacillus fusiformis, a spore-forming opportunistic pathogen. Products were distributed to healthcare providers and doctor's offices. High-risk patients: immunocompromised, diabetics, patients with open wounds.
Nalpac DTF Sexual Chocolate (April 6) Voluntary nationwide recall of DTF Sexual Chocolate for undeclared sildenafil and tadalafil. PDE-5 inhibitors in an unlabeled food product create a serious interaction risk with nitrate-containing prescription drugs. Distribution channel not specified, but the product category (adult novelty food/supplement) frequently moves through e-commerce and specialty retail.
Blueroot Health — Vital Nutrients Aller-C (April 10) Expanded voluntary allergy alert for Vital Nutrients Aller-C dietary supplements due to undeclared egg, hazelnut, and soy. The expansion signals that the original allergen-cross-contact investigation broadened after additional lot testing. Consumers with tree nut, egg, or soy allergies face anaphylaxis risk. Allergen recalls in the supplement channel remain one of the most consistent recall drivers quarter over quarter.
Regulatory Notices
FAERS E2B(R3) Implementation Schedule (April 6) FDA published the implementation schedule for electronic submission of postmarketing Individual Case Safety Reports using ICH E2B(R3) standards to the FDA Adverse Event Monitoring System. Relevant for drug and biologic manufacturers with postmarketing pharmacovigilance obligations.
STRATTERA Generics Cleared (April 6) FDA determined that Strattera (atomoxetine HCl) in all capsule strengths was not withdrawn from sale for safety or effectiveness reasons. This clears the path for ANDA approvals referencing Strattera.
LOARGYS Priority Review Voucher (April 7) FDA issued a Priority Review Voucher to the sponsor of LOARGYS (pegzilarginase-nbln) under the rare pediatric disease program. Routine administrative notice; no action required.
Wellcovorin NDA Withdrawal (April 10) GlaxoSmithKline withdrew the New Drug Application for Wellcovorin (leucovorin calcium) tablets, EQ 5 mg and EQ 25 mg base. Commercial withdrawal (not a safety determination), but FDA's notice formally closes the reference listed drug — any generics referencing this NDA need to transition to an alternative RLD.
Guidance
Bioanalytical Method Validation for Biomarkers (April 10) FDA released new guidance on bioanalytical method validation specific to biomarkers. Relevant for sponsors relying on biomarker endpoints in clinical trials — the validation standards for exploratory vs. surrogate-endpoint biomarkers continue to diverge, and this guidance sharpens the expectations.
Also This Week
-
Medline Industries (April 7) — CGMP/QSR warning letter for its Glens Falls, NY facility. Failures in CAPA procedures (syringe/manifold disconnections linked to silicone contamination), inadequate cleanroom maintenance, and unverified luer connector design changes. Medline has initiated a product removal but must address systemic quality system gaps. Issued by CDRH.
-
Global Tobacco LLC (April 7) — Warning letter for distributing "RUSH Mango Freeze 12MG" nicotine pouches without premarket authorization. Adulterated and misbranded under the Tobacco Control Act.
-
Life Plus Style Gourmet LLC (April 7) — Warning letter for failure to develop or maintain a Foreign Supplier Verification Program for imported foods. Office of Inspections and Investigations.
-
Dr. Ehsan Sadri (April 7) — Clinical investigator warning for enrolling subjects in an ophthalmic drug trial without meeting protocol eligibility criteria (corneal endothelial cell density and intraocular pressure thresholds). Violation of 21 CFR 312.60.
Context: Week-Over-Week
| Type | This Week | Prior Week (Mar 28–Apr 3) |
|---|---|---|
| Warning Letters | 12 | 4 |
| Recalls | 3 | 48 |
| Safety Alerts | 3 | 3 |
| Guidance | 1 | 3 |
| Notices | 8 | 15 |
| Total | 27 | 73 |
The recall count drop (48 → 3) reflects that the prior week was an unusually heavy enforcement period following FDA's internal pipeline clearing. Warning letter volume is up sharply, driven almost entirely by the GLP-1 sweep.
Sourced from Policy Canary database — 27 items indexed, April 4–10, 2026.
Get this in your inbox every Friday.
Free FDA intelligence digest. No account required.
